Ordenar

Buscar

01/02/2026 Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations
Döhner, H, Schuh, AC, Recher, C, O'Nions, J, Aldoss, I, Piérola, AA, Allred, AJ, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Daskalakis, N, Della Porta, MG, D'Souza, A, Dugan, J, Esteve, J, Fathi, AT, Ferrante, L, Gaj, S, Garciaz, S, Diaz, AG, Salamero, O, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Paniagua, SG, Sackey, N, Sauer, T, Shastri, PN, Searle, E, Tovar, N, Trancucci, D, Vallet, N, Vaughan, L, Vyas, P, Wei, AH, Rölling, C. Bleximenib in Combination with Intensive Chemotherapy: A phase 1b Study in Patients with Newly Diagnosed Acute Myeloid Leukemia with KMT2A or NPM1 Alterations. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).
01/02/2026 Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis
Lopez-Pereira, P, Domínguez, SR, Martin-Moro, F, Caballero, AC, García, AL, Benito, BD, Sarto, MF, Vicente, FD, Marín, JL, Marino, SP, Jiménez-Ubieto, A, Cabirta, A, Gutiérrez, NC, Chulvi, MJL, Puyuelo, A, Prat, AM, Coello, AP, García-Lerma, E, Vilchez, SM. Outcomes of de novo primary central nervous system lymphoma using the MATRix regimen for induction followed by thiotepa-based conditioning: a GELTAMO analysis. BONE MARROW TRANSPLANTATION. 2026; 61(2)DOI:10.1038/s41409-025-02772-2. PMID:41310181. IF:5.200(Q1/1D).
01/02/2026 Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
Westin, J, Chavez, JC, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, García-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma. Transplantation And Cellular Therapy. 2026; 32(2)DOI:. PMID:. IF:4.400(Q1/1D).
01/02/2026 The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review
Di Bello, F, Gallioli, A, Pecoraro, A, Prudhomme, T, Piana, A, Marco, BB, Haberal, HB, Dönmez, MI, Lopez-Abad, A, Cannoletta, D, Mancon, S, Guirado, L, Facundo, C, Kanashiro, AK, Gavrilov, P, Rodriguez-Faba, O, Gaya, JM, Breda, A, Territo, A. The role of artificial intelligence in predicting graft survival in kidney transplantation: a systematic review. Minerva Urology And Nephrology. 2026; 78(1)DOI:10.23736/S2724-6051.25.06559-0. PMID:41697205. IF:4.200(Q1/2D).